Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.47 -1.26 (-0.80%)
Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Nasdaq, S&P 500 Futures Plunge After Trump's Comments And ASML's Weak Forecast Deepens Tech Sell-Off: AI Narrative May Be Priced In, Says Analyst
Sentiment will likely reverse course, with the index futures trading notably lower early Wednesday. The recent run-up ideally should render the mood cautious, and the caution may intensify as the first... 
Via Benzinga
Topics Artificial Intelligence Government Stocks
Exposures Artificial Intelligence Political US Equities
3 Dividend Stocks With 3%+ Yields to Upgrade Your Annual Income
These high-yield dividend stocks will ensure steady quarterly income and help your money grow at little risk. 
Via InvestorPlace
Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered Guidance
The Dow giant reported before the open. Shares are in a long downtrend. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
From Johnson & Johnson
Via Business Wire
Smart Money Is Betting Big In JNJ Options
Via Benzinga
NYSE:JNJ: good value for what you're paying.
JOHNSON & JOHNSON (NYSE:JNJ) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
Johnson & Johnson reports Q2 2024 results
From Johnson & Johnson
Via Business Wire
ASML, United Airlines And 3 Other Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Dow Jones Closes At Record High As Traders Turn Bullish Amid Hopes Of Fed Cutting Rates In September
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, with the index remaining in the "Greed" zone on Tuesday. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Johnson & Johnson has beaten earnings per share in more than 10 straight quarters. Will the trend continue in Q2? 
Via Benzinga
3 Safe Dividend Kings to Recession-Proof Your Portfolio
These safe dividend kings belong to an elite club of companies that have paid dividends for more than 50 years. 
Via InvestorPlace
Johnson & Johnson: Bullish Charts Signal Strong Setup Before Q2 Earnings
Johnson & Johnson reports Q2 earnings, expected EPS of $2.7 and revenues of $22.3B. Stock is bullish, above key moving averages. 
Via Benzinga
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings
JNJ to release 2Q financial results on July 17. Expected earnings $2.70/share, revenue $22.29B. Investors eye 3.32% dividend yield for gains. 
Via Benzinga
If You Can Only Buy One Dow Stock in July, It Better Be One of These 3 Names
These dow stocks to buy are well-positioned to provide significant returns to investors due to their high growth potential. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Dow Closes At New High As Q2 Earnings Season Heats Up
It’s a great start to the trading week. After months of trailing its major-index brethren, the Dow Jones reaches today’s closing bell at a new record high: 40,211. Q2 earnings are coming in well so... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
From NKGen Biotech
Via GlobeNewswire
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies stand out for their pedigrees, robust financials, and future growth prospects. 
Via The Motley Fool
2 Healthcare Stocks to Buy Hand Over Fist This Month
They don't have the most exciting businesses, but they have a lot to offer nonetheless. 
Via The Motley Fool
Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years
Following a lackluster big bank earnings, market participants now turn their attention to the unfolding week, expecting the trend to reverse. 
Via Benzinga
3 High-Yield Dividend Stocks That Still Look Like Bargains
The prices of these reliable dividend payers haven't kept pace with the frothy stock market. 
Via The Motley Fool
MarketBeat Week in Review – 7/8 - 7/12
Stocks took investors on quite a ride this week, with the S&P 500 hitting a new record high, then falling back on Thursday before rallying to end the week 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
3 Key Earnings Reports To Watch Next Week
With the 2024 Q2 earnings season kicking into a much higher gear next week, there are several reports investors should keep on their radars, including those from Netflix, Taiwan Semiconductor, and... 
Via Talk Markets
3 Essential Stocks for Building a Recession-Proof Portfolio
Secure your portfolio with these three recession-proof stocks, chosen for their consistent performance and long-term growth. 
Via InvestorPlace
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
From Johnson & Johnson
Via Business Wire
3 Magnificent Dow Stocks That Are No-Brainer Buys for the Second Half of 2024
Among the Dow Jones Industrial Average's 30 time-tested components, there are three that stand out as phenomenal buys right now. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Undervalued Stocks Set to Outperform the Market in 2024
Discover the top three undervalued stocks poised for growth in the restaurant, pharmaceutical and footwear industries. 
Via InvestorPlace
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs
Johnson & Johnson is set to release its Q2 2024 earnings on July 17. Analysts estimate $22.29 billion in sales and an EPS of $2.71. 
Via Benzinga
Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing
Emergent BioSolutions and Janssen Pharmaceuticals settle disputes over SARS-CoV-2 vaccine manufacturing with a $50 million agreement, resolving all related claims and arbitration. 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.